Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

被引：20

作者：

Engert, A. ^{[1
,2
]}

Eichenauer, D. A. ^{[1
,2
]}

Dreyling, M. ^{[3
]}

机构：

[1] Univ Hosp Koln, Dept Internal Med 1, Cologne, Germany

[2] GHSG, Cologne, Germany

[3] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Dept Med 3, Munich, Germany

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷

关键词：

STEM-CELL TRANSPLANTATION; CHEMOTHERAPY; STANDARD; REGIMEN; DISEASE;

D O I：

10.1093/annonc/mdp144

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：108 / 109

页数：2

共 11 条

[1] Long-term follow-up of Hodgkin's disease trial [J].

Canellos, GP ;

Niedzwiecki, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) :1417-1418

[2] Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome [J].

Dann, Eldad J. ;

Bar-Shalom, Rachel ;

Tamir, Ada ;

Haim, Nissim ;

Ben-Shachar, Menachem ;

Avivi, Irit ;

Zuckerman, Tzila ;

Kirschbaum, Mark ;

Goor, Odelia ;

Libster, Diana ;

Rowe, Jacob M. ;

Epelbaum, Ron .

BLOOD, 2007, 109 (03) :905-909

[3] Relapsed and refractory Hodgkin Lymphoma: Transplantation strategies and novel therapeutic options [J].

David K.A. ;

Mauro L. ;

Evens A.M. .

Current Treatment Options in Oncology, 2007, 8 (5) :352-374

[4] Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].

Diehl, V ;

Franklin, J ;

Pfreundschuh, M ;

Lathan, B ;

Paulus, U ;

Hasenclever, D ;

Tesch, H ;

Herrmann, R ;

Dörken, B ;

Müller-Hermelink, H ;

Dühmke, E ;

Loeffler, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395

[5]

Horning Sandra J, 2007, Hematology Am Soc Hematol Educ Program, P197

[6] FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma [J].

Kasamona, Yvette L. ;

Wah, Richard L. .

CURRENT OPINION IN ONCOLOGY, 2008, 20 (02) :206-219

[7] Ifosfamide, gemcitabine, and vinorelbine: a now induction regimen for refractory and relapsed Hodgkin's lymphoma [J].

Santoro, Armando ;

Magagnoli, Massimo ;

Spina, Michele ;

Pinotti, Graziella ;

Siracusano, Licia ;

Michieli, Mariagrazia ;

Nozza, Andrea ;

Sarina, Barbara ;

Morenghi, Emanuela ;

Castagna, Luca ;

Tirelli, Umberto ;

Balzarotti, Monica .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01) :35-41

[8] Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial [J].

Schmitz, N ;

Pfistner, B ;

Sextro, M ;

Sieber, M ;

Carella, AM ;

Haenel, M ;

Boissevain, F ;

Zschaber, R ;

Müller, P ;

Kirchner, H ;

Lohri, A ;

Decker, S ;

Koch, B ;

Hasenclever, D ;

Goldstone, AH ;

Diehl, V .

LANCET, 2002, 359 (9323) :2065-2071

[9] Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma:: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG) [J].

Schulz, Holger ;

Rehwald, Ute ;

Morschhauser, Franck ;

Elter, Thomas ;

Driessen, Christoph ;

Ruediger, Thomas ;

Borchmann, Peter ;

Schnell, Roland ;

Diehl, Volker ;

Engert, Andreas ;

Reiser, Marcel .

BLOOD, 2008, 111 (01) :109-111

[10] Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the lymphoma working party of the European group for blood and marrow transplantation [J].

Sureda, Anna ;

Robinson, Stephen ;

Canals, Carmen ;

Carella, Angela M. ;

Boogaerts, Marc A. ;

Caballero, Dolores ;

Hunter, Ann E. ;

Kanz, Lothar ;

Slavin, Shimon ;

Cornelisson, Jan J. ;

Gramatzki, Martin ;

Niederwieser, Dietger ;

Russell, Nigel H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :455-462

← 1 2 →